JNJ-79635322
Phase 1, First-in-Human, Dose Escalation Study of JNJ-79635322, a Trispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated AL Amyloidosis
Near Add Your Location
Sorting 15 by
Memorial Sloan Kettering Cancer Center
New York, NY
- Accepting patients
- Show Principal Investigator
- Accepting patients
Memorial Sloan Kettering Bergen
Montvale, NJ
- Accepting patients
- Show Principal Investigator
Memorial Sloan Kettering Basking Ridge
Basking Ridge, NJ
- Accepting patients
- Show Principal Investigator
- Accepting patients
- Accepting patients
Memorial Sloan Kettering Commack
Commack, NY
- Accepting patients
- Show Principal Investigator
Memorial Sloan Kettering Nassau
Uniondale, NY
- Accepting patients
- Show Principal Investigator
Abramson Cancer Center - University of Pennsylvania (UPENN)
University of Pennsylvania
Philadelphia, PA
- Accepting patients
- Accepting patients
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.